相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
Martin L. Sos et al.
CANCER RESEARCH (2009)
In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
Klaus P. Hoeflich et al.
CLINICAL CANCER RESEARCH (2009)
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions
Martin L. Sos et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors
Bijay S. Jaiswal et al.
PLOS ONE (2009)
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy
Samanthi A. Perera et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
Christine A. Pratilas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis
Neil P. Shah et al.
CANCER CELL (2008)
Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110α
Eli R. Zunder et al.
CANCER CELL (2008)
Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy
Bret B. Friday et al.
CLINICAL CANCER RESEARCH (2008)
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Adrian J. Folkes et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding et al.
NATURE (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The genomic landscapes of human breast and colorectal cancers
Laura D. Wood et al.
SCIENCE (2007)
Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors
Lucia Regales et al.
PLOS ONE (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models
Hongbin Ji et al.
CANCER RESEARCH (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
A common signaling cascade may underlie addiction to the Src, BCR-ABL, and EGF receptor oncogenes
Sreenath V. Sharma et al.
CANCER CELL (2006)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Qi-Wen Fan et al.
CANCER CELL (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
BRAF mutation predicts sensitivity to MEK inhibition
DB Solit et al.
NATURE (2006)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
JA Engelman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control
R Loewith et al.
MOLECULAR CELL (2002)
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action
K Hara et al.
CELL (2002)
MTOR interacts with Raptor to form a nutrient-sensitive complex that signals to the cell growth machinery
DH Kim et al.
CELL (2002)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
H Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
分享论文
